What is the appropriate evaluation and management for a patient who develops joint pain after an episode of diarrhea and has associated uveitis?

Reactive Arthritis with Uveitis: Diagnosis and Management

This clinical triad of post-infectious arthritis, diarrhea, and uveitis strongly suggests reactive arthritis (ReA), most likely HLA-B27-associated spondyloarthritis, requiring immediate ophthalmologic evaluation and coordinated rheumatologic care.

Immediate Diagnostic Approach

Ophthalmologic Assessment

Urgent ophthalmology referral within 24-48 hours is mandatory to prevent vision-threatening complications 1. The uveitis in spondyloarthritis typically presents as:

• Acute anterior uveitis (AAU): sudden onset, unilateral, recurrent pattern
• Symptoms: eye pain, photophobia, blurred vision, redness
• Requires slit-lamp examination to confirm anterior chamber cells and differentiate from episcleritis 1

Rheumatologic Workup

Obtain the following targeted investigations:

• HLA-B27 typing: appropriate for recurrent anterior uveitis 2
• Serologic testing for syphilis: mandatory screening 2
• Chest radiography: to exclude sarcoidosis and tuberculosis 2
• Stool cultures if diarrhea is ongoing (to identify triggering organisms: Salmonella, Shigella, Campylobacter, Yersinia)
• Inflammatory markers (ESR, CRP)
• Evaluate for sacroiliitis and spondyloarthritis features (imaging if indicated)

Avoid routine testing for Lyme serology, ANA, ACE levels, or tuberculin skin tests unless specifically indicated by history, as these yield high false-positive rates in low-prevalence populations 2.

Treatment Strategy

Ocular Management

Topical corticosteroids (prednisolone acetate 1% or dexamethasone) are first-line treatment for acute anterior uveitis 3, 1. For isolated short-lived AAU episodes in patients already on systemic therapy, treat with topical glucocorticoids first rather than immediately escalating systemic immunosuppression 4.

Systemic Therapy for Arthritis and Uveitis Prevention

For patients with spondyloarthritis and recurrent/refractory uveitis, monoclonal antibody TNF inhibitors (adalimumab > infliximab > golimumab) are strongly preferred over other biologics 5, 6. This recommendation is critical because:

• Adalimumab and infliximab significantly reduce uveitis recurrence rates (13.6 and 27.5 per 100 patient-years respectively) compared to etanercept (60.3 per 100 patient-years) 6
• Etanercept should NOT be used for spondyloarthritis-associated uveitis as it is ineffective and may increase flare frequency 7, 8
• IL-17 inhibitors (secukinumab, ixekizumab) are contraindicated or should be avoided as they can trigger or worsen inflammatory bowel disease and have not demonstrated efficacy in preventing uveitis 5, 6

Treatment Algorithm

1. Acute phase: Topical corticosteroids for uveitis + NSAIDs for arthritis
2. If recurrent uveitis (≥2 episodes) or persistent arthritis: Initiate monoclonal antibody TNF inhibitor (adalimumab preferred)
3. Sulfasalazine consideration: Decreases frequency, duration, and severity of uveitis episodes and can be used prophylactically in spondyloarthritis 9
4. Avoid: Etanercept, IL-17 inhibitors if IBD present or suspected

Monitoring Requirements

Establish collaborative care between ophthalmology and rheumatology 3. Patients require:

• Education on AAU warning signs (eye pain, redness, photophobia, vision changes) to decrease treatment delay 4
• Regular ophthalmologic screening even when asymptomatic
• Assessment for inflammatory back pain and other spondyloarthritis features (50-60% of uveitis cases lead to spondyloarthritis diagnosis) 9

Critical Pitfalls to Avoid

1. Delaying ophthalmology referral: Vision loss can occur; same-day or next-day evaluation is essential
2. Using etanercept: Ineffective for uveitis prevention and may worsen outcomes
3. Prescribing IL-17 inhibitors when IBD suspected: Can precipitate or exacerbate Crohn's disease
4. Over-testing: Avoid shotgun laboratory approaches; focus on HLA-B27, syphilis serology, and chest imaging
5. Treating uveitis in isolation: This is a systemic inflammatory condition requiring coordinated subspecialty management

The prognosis for vision is generally good with prompt treatment, though 50-60% experience recurrent episodes 9. The key to preventing complications is early recognition, appropriate systemic therapy selection, and maintaining close ophthalmologic surveillance.